> top > docs > PubMed:35432355 > annotations

PubMed:35432355 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-59 Sentence denotes Perspectives of JAK Inhibitors for Large Vessel Vasculitis.
T2 60-246 Sentence denotes Vasculitis is an inflammation of the blood vessels caused by autoimmunity and/or autoinflammation, and recent advances in research have led to a better understanding of its pathogenesis.
T3 247-320 Sentence denotes Glucocorticoids and cyclophosphamide have long been the standard of care.
T4 321-468 Sentence denotes However, B-cell depletion therapy with rituximab has become available for treating antineutrophil cytoplasmic antibody-associated vasculitis (AAV).
T5 469-605 Sentence denotes More recently, avacopan, an inhibitor of the complement 5a receptor, was shown to have high efficacy in remission induction against AAV.
T6 606-657 Sentence denotes Thus, treatment options for AAV have been expanded.
T7 658-883 Sentence denotes In contrast, in large vessel vasculitis (LVV), including giant cell arteritis and Takayasu arteritis, tocilizumab, an IL-6 receptor antagonist, was shown to be effective in suppressing relapse and has steroid-sparing effects.
T8 884-977 Sentence denotes However, the relapse rate remains high, and other therapeutic options have long been awaited.
T9 978-1094 Sentence denotes In the last decade, Janus kinase (JAK) inhibitors have emerged as therapeutic options for rheumatoid arthritis (RA).
T10 1095-1257 Sentence denotes Their efficacy has been proven in multiple studies; thus, JAK inhibitors are expected to be promising agents for treating other rheumatic diseases, including LVV.
T11 1258-1375 Sentence denotes This mini-review briefly introduces the mechanism of action of JAK inhibitors and their efficacy in patients with RA.
T12 1376-1559 Sentence denotes Then, the pathophysiology of LVV is updated, and a rationale for treating LVV with JAK inhibitors is provided with a brief introduction of our preliminary results using a mouse model.
T13 1560-1679 Sentence denotes Finally, we discuss the newly raised safety concerns regarding JAK inhibitors and future perspectives for treating LVV.
T1 0-59 Sentence denotes Perspectives of JAK Inhibitors for Large Vessel Vasculitis.
T2 60-246 Sentence denotes Vasculitis is an inflammation of the blood vessels caused by autoimmunity and/or autoinflammation, and recent advances in research have led to a better understanding of its pathogenesis.
T3 247-320 Sentence denotes Glucocorticoids and cyclophosphamide have long been the standard of care.
T4 321-468 Sentence denotes However, B-cell depletion therapy with rituximab has become available for treating antineutrophil cytoplasmic antibody-associated vasculitis (AAV).
T5 469-605 Sentence denotes More recently, avacopan, an inhibitor of the complement 5a receptor, was shown to have high efficacy in remission induction against AAV.
T6 606-657 Sentence denotes Thus, treatment options for AAV have been expanded.
T7 658-883 Sentence denotes In contrast, in large vessel vasculitis (LVV), including giant cell arteritis and Takayasu arteritis, tocilizumab, an IL-6 receptor antagonist, was shown to be effective in suppressing relapse and has steroid-sparing effects.
T8 884-977 Sentence denotes However, the relapse rate remains high, and other therapeutic options have long been awaited.
T9 978-1094 Sentence denotes In the last decade, Janus kinase (JAK) inhibitors have emerged as therapeutic options for rheumatoid arthritis (RA).
T10 1095-1257 Sentence denotes Their efficacy has been proven in multiple studies; thus, JAK inhibitors are expected to be promising agents for treating other rheumatic diseases, including LVV.
T11 1258-1375 Sentence denotes This mini-review briefly introduces the mechanism of action of JAK inhibitors and their efficacy in patients with RA.
T12 1376-1559 Sentence denotes Then, the pathophysiology of LVV is updated, and a rationale for treating LVV with JAK inhibitors is provided with a brief introduction of our preliminary results using a mouse model.
T13 1560-1679 Sentence denotes Finally, we discuss the newly raised safety concerns regarding JAK inhibitors and future perspectives for treating LVV.